Skip to main content
. 2019 Sep 20;98(38):e17208. doi: 10.1097/MD.0000000000017208

Figure 5.

Figure 5

Serum levels of protein markers in the study population classified according with its pharmacologic therapy. The inflammatory bowel disease cases were classified according their pharmacologic therapy and the markers included in the study were compared between groups. Figure shows the results of these analyses for the markers classified as (A) chemokines, (B) antiinflammatory cytokines, (C) proinflammatory cytokines, and (D) growth factors. P-values were obtained from the comparison of circulating levels of the protein markers evaluated in the study, considering the control group as reference. ∗P < .05, ∗∗P < .005. 5-ASA = 5-aminosalicylic acid, FGF-2 = fibroblast growth factor 2, G-CSF = granulocyte colony-stimulating factor, GM-CSF = granulocyte-macrophage CSF, IFN-γ = interferon gamma, IL = interleukin, IP-10 = interferon-induced protein 10, MCP-1 = monocyte chemoattractant protein 1, MIP-1 = macrophage inflammatory protein 1, PDGF-BB = platelet-derived growth factor BB, RANTES = term used for chemokine ligand 5 (CCL-5), TNF-α = tumor necrosis factor alpha, VEGF = vascular endothelial growth factor.